First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma

BACKGROUND: DT01 is a DNA-repair inhibitor preventing recruitment of DNA-repair enzymes at damage sites. Safety, pharmacokinetics and preliminary efficacy through intratumoural and peritumoural injections of DT01 were evaluated in combination with radiotherapy in a first-in-human phase I trial in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Tourneau, C, Dreno, B, Kirova, Y, Grob, J J, Jouary, T, Dutriaux, C, Thomas, L, Lebbé, C, Mortier, L, Saiag, P, Avril, M F, Maubec, E, Joly, P, Bey, P, Cosset, J M, Sun, J S, Asselain, B, Devun, F, Marty, M E, Dutreix, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891504/
https://www.ncbi.nlm.nih.gov/pubmed/27140316
http://dx.doi.org/10.1038/bjc.2016.120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891504/
https://www.ncbi.nlm.nih.gov/pubmed/27140316
http://dx.doi.org/10.1038/bjc.2016.120

Ejemplares similares